Alliance Global Partners lowered the firm’s price target on Tenon Medical (TNON) to $2.50 from $3 and keeps a Buy rating on the shares, citing lower forecasts after Tenon reported Q1 results that were within the firm’s expectations, including a revenue shortfall offset by lower expenses.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNON: